失调
微生物群
肠道菌群
医学
粪便细菌疗法
临床试验
结直肠癌
免疫学
肠道微生物群
不利影响
重症监护医学
生物信息学
癌症
内科学
艰难梭菌
生物
微生物学
抗生素
作者
Sona Ciernikova,Aneta Sevcikova,Ľuboš Drgoňa,Michal Mego
标识
DOI:10.1016/j.bbcan.2023.188990
摘要
Treatment resistance, together with acute and late adverse effects, represents critical issues in the management of cancer patients. Promising results from preclinical and clinical research underline the emerging trend of a microbiome-based approach in oncology. Favorable bacterial species and higher gut diversity are associated with increased treatment efficacy, mainly in chemo- and immunotherapy. On the other hand, alterations in the composition and activity of gut microbial communities are linked to intestinal dysbiosis and contribute to high treatment-induced toxicity. In this Review, we provide an overview of studies concerning gut microbiota modulation in patients with solid and hematologic malignancies with a focus on probiotics, prebiotics, postbiotics, and fecal microbiota transplantation. Targeting the gut microbiome might bring clinical benefits and improve patient outcomes. However, a deeper understanding of mechanisms and large clinical trials concerning microbiome and immunological profiling is warranted to identify safe and effective ways to incorporate microbiota-based interventions in routine clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI